[A26-32] Tezepelumab (chronic rhinosinusitis with nasal polyps) – Addendum to Project A25-145
Last updated 07.05.2026
Project no.:
A26-32
Commission:
Commission awarded on 24.03.2026 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Airways and respiratory system
Add-on therapy for adults with severe chronic rhinosinusitis with nasal polyps for whom therapy with systemic corticosteroids, and/or surgery do not provide adequate disease control
After addendum now: hint of a non-quantifiable added benefit
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
https://doi.org/10.60584/A26-32
| Project no. | Title | Status |
|---|---|---|
| A25-145 | Tezepelumab (chronic rhinosinusitis with nasal polyps) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
07-05-2026 A G-BA decision was published.
G-BA documents on this decision